Amneal Pharmaceuticals
AMRX
181 hedge funds and large institutions have $874M invested in Amneal Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 71 increasing their positions, 43 reducing their positions, and 29 closing their positions.
339% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $355K
65% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 43
34% more capital invested
Capital invested by funds: $651M → $874M (+$223M)
24% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 29
9.75% more ownership
Funds ownership: 34.83% → 44.57% (+9.7%)
3% more funds holding
Funds holding: 175 → 181 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$138M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$31.2M |
| 3 |
BlackRock
New York
|
+$13.4M |
| 4 |
HAI
Hennessy Advisors Inc
Novato,
California
|
+$8.82M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$48.6M |
| 2 |
Teacher Retirement System of Texas
Austin,
Texas
|
-$4.57M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$4.24M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.23M |
| 5 |
Neuberger Berman Group
New York
|
-$2.24M |
AMRX Hedge Fund Activity: Q2 2024 in Review
181 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2024, worth a combined $874M — up 34% from $651M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AMRX positions and 29 closed out — a net gain of 7 holders — while 71 added to existing stakes and 43 trimmed.
The largest buyer was UBS Group, adding an estimated $138M. The largest seller was Fosun International, cutting an estimated $48.6M.
- 181 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2024, up from 175 in Q1 2024.
- Funds reported $874M of Amneal Pharmaceuticals stock for Q2 2024, up 34% quarter-over-quarter.
- 36 funds opened new Amneal Pharmaceuticals positions in Q2 2024 and 29 closed out, a net change of +7 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2024 was UBS Group, an estimated $138M added.
- The largest Amneal Pharmaceuticals seller in Q2 2024 was Fosun International, an estimated $48.6M sold.
Based on aggregated 13F filings for Q2 2024.